Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Spine-Tech/Sulzer Medica pact

This article was originally published in The Gray Sheet

  • News

Executive Summary

Spine-Tech/Sulzer Medica pact: Sulzer Orthopedics Biologics unit of Sulzer Medica and Spine-Tech plan to file investigational device exemption shortly to evaluate use of Spine-Tech's BAK interbody fusion system with Sulzer's Ne-Osteo bovine-derived bone morphogenic protein as an alternative to use of autograft in spinal fusion surgeries. Ne-Osteo also is under investigation as a substitute for autograft in posterior lumbar spine fusion, Sulzer says...

Table

View full table

Tags:
Latest Headlines

EU Regulatory Roundup, April 2024: EU On Cusp Of Regulatory Shifts Amidst Political Change

Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold

It’s Official: FDA Drops Final Rule On LDTs

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

See All
UsernamePublicRestriction

Register

MT008910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By